Renal Response to Acute Neutral Endopeptidase Inhibition in Mild and Severe Experimental Heart Failure
- 14 December 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (24) , 2443-2448
- https://doi.org/10.1161/01.cir.100.24.2443
Abstract
Background —Neutral endopeptidase 24.11 (NEP) is a metalloprotease that is localized in the greatest abundance in the kidney and degrades natriuretic peptides, such as atrial natriuretic peptide (ANP). Mild congestive heart failure (CHF) is characterized by increases in circulating ANP without activation of the renin-angiotensin-aldosterone system (RAAS) or sodium retention. In contrast, severe CHF is characterized by sodium retention and coactivation of both ANP and the RAAS. Methods and Results —We defined the acute cardiorenal actions of the NEP inhibitor candoxatrilat (8 μg · kg −1 · min −1 ) in 4 groups of anesthetized dogs (normal, n=8; mild CHF, n=6; severe CHF, n=5; and severe CHF with chronic AT 1 receptor antagonism, n=5). Mild CHF was produced by rapid ventricular pacing at 180 bpm for 10 days and severe CHF at 245 bpm for 10 days. In mild CHF, urinary sodium excretion and glomerular filtration rate were greatest in response to acute NEP inhibition compared with the response in either control animals or those with severe CHF. Furthermore, an increase in glomerular filtration rate was observed only in mild CHF in association with increases in renal blood flow and decreases in renal vascular resistance and distal tubular sodium reabsorption. Urinary ANP and cGMP excretion, markers for renal biological actions of ANP, were greatest in mild CHF. The renal actions observed in mild CHF were attenuated in severe CHF and not restored by chronic AT 1 receptor antagonism. Conclusions —The results of the present study demonstrate that acute NEP inhibition in mild CHF results in marked increases in renal hemodynamics and sodium excretion that exceed that observed in control animals and severe CHF. These studies underscore the potential therapeutic role for NEP inhibition to enhance renal function in mild CHF, an important phase of CHF that is marked by selective activation of endogenous ANP in the absence of an activated RAAS.Keywords
This publication has 25 references indexed in Scilit:
- Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic HypertensionJAMA, 1997
- A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction.Journal of Clinical Investigation, 1995
- Atrial natriuretic peptide in heart failureJournal of the American College of Cardiology, 1993
- Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection FractionsNew England Journal of Medicine, 1992
- Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.Journal of Clinical Investigation, 1991
- Heart Failure Augments the Cardiovascular and Renal Effects of Neutral Endopeptidase Inhibition in RatsJournal of Cardiovascular Pharmacology, 1991
- Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factorKidney International, 1990
- Role of endopeptidase‐24.11 in the inactivation of atrial natriuretic peptideFEBS Letters, 1988
- Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivoKidney International, 1987
- Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the HumanScience, 1986